Clinical Trial: Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06995872) titled 'Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma' on May 28.

Brief Summary: Background:

Neuroblastoma is a type of cancer that causes tumors in nerves. It affects mainly infants and toddlers, and it causes about 15 percent of cancer-related deaths in children.

Objective:

To test a new drug (rhIL-15), combined with 3 standard cancer drugs, in people with neuroblastoma.

Eligibility:

People aged 3 to 35 years with neuroblastoma that did not respond or returned after standard treatment.

Design:

Participants will be screened. They will have a...